Go Deep
Oncolytics Biotech Inc.
Oncolytics Biotech Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -23,979 | -1.6 | -11.64 | -0.15 | 51.87 |
| Oct 2026 | -23,265 | -1.4 | -10.59 | -0.15 | 47.18 |
| Oct 2026 | -25,239 | -1.4 | -10.55 | -0.15 | 47.06 |
| Oct 2026 | -25,272 | -1.4 | -10.60 | -0.15 | 47.28 |
| Oct 2026 | -25,457 | -1.5 | -10.87 | -0.15 | 48.37 |
| Oct 2026 | -25,296 | -1.4 | -10.63 | -0.15 | 47.21 |
| Oct 2026 | -25,326 | -1.4 | -10.68 | -0.15 | 47.61 |
Oncolytics Biotech Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -9,442,000.0 | -9,243,000.0 | -9,177,897.1 | -10,346,685.8 |
| EPS | -0.1 | -0.1 | — | -0.1 |
Oncolytics Biotech Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -28,759,000.0 | -22,794,000.0 | -20,919,644.2 | -18,298,703.2 | — |
| EPS | -0.3 | -0.3 | -0.3 | -0.3 | — |
Oncolytics Biotech Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 7,582,000.0 | 13,421,000.0 | 29,262,777.0 | 27,508,104.9 | — |
| Total Liabilities | 11,381,000.0 | 10,123,000.0 | 8,485,602.3 | 7,981,137.6 | — |
| Total Equity | -3,799,000.0 | 3,298,000.0 | 20,777,174.7 | 19,526,967.3 | — |
Owes vs Owns
Oncolytics Biotech Inc. owed $1.80 for every $1 it owned in Jun 2026, up from $0.29 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.80× | 1.50× | 0.75× | 0.29× | 0.29× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Oncolytics Biotech Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 68.6%Receivables 7.6%Fixed assets (tangible) 9.7%Other assets 14.1%
How it's funded — Dec 2025
Short-term debt 1.7%Long-term debt 3.3%Payables 30.8%Other liabilities 64.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 5.2 | 11.1 | 26.3 | 23.7 |
| Receivables | 0.6 | 0.0 | 0.0 | 0.4 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.7 | 1.0 | 0.5 | 0.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.1 | 1.3 | 2.4 | 3.0 |
| Liabilities & equity | ||||
| Short-term debt | 0.2 | 0.2 | 0.1 | 0.2 |
| Long-term debt | 0.4 | 0.6 | 0.2 | 0.1 |
| Payables | 3.5 | 0.8 | 0.8 | 1.7 |
| Other liabilities | 7.3 | 8.6 | 7.4 | 6.0 |
| Shareholders' equity | -3.8 | 3.3 | 20.8 | 19.5 |
| Net tangible assets | -3.8 | 3.3 | 20.8 | 19.5 |
Oncolytics Biotech Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -20,112,000.0 | -19,883,000.0 | -21,444,293.7 | -17,208,222.8 | — |
| Investing Activities | -6,000.0 | -174,000.0 | 15,243,479.6 | -15,033,156.5 | — |
| Financing Activities | 14,120,000.0 | 5,028,000.0 | 24,117,292.3 | 8,992,779.3 | — |